Fennec Pharmaceuticals Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Fennec Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fennec Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Fennec Pharmaceuticals.

Fennec Pharmaceuticals Inc. (TSE:FRX) announced its earnings results on Tuesday, March, 30th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08. The biopharmaceutical company earned $0.22 million during the quarter.
View Fennec Pharmaceuticals' earnings history.

Fennec Pharmaceuticals' stock was trading at C$9.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FRX stock has decreased by 4.5% and is now trading at C$8.61.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Fennec Pharmaceuticals include Oxford Biomedica (OXB), 4D Molecular Therapeutics (FDMT), Bolt Biotherapeutics (BOLT), Pharming Group (PHAR), Gracell Biotechnologies (GRCL), iTeos Therapeutics (ITOS), Pharvaris B.V. (PHVS), Finch Therapeutics Group (FNCH), Achilles Therapeutics plc American Depositary Shares (ACHL), 22nd Century Group (XXII), Ergomed (ERGO), Biotest Aktiengesellschaft (BIO), Burcon NutraScience (BU), Aptose Biosciences (APS) and VectivBio (VECT).
View all of FRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Encanto Potash (EPO), Acadian Timber (ADN), (AD), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AutoCanada (ACQ), ATCO (ACO.X), Accord Financial (ACD), Aurora Cannabis (ACB), Air Canada (AC) and Barrick Gold (ABX).

Fennec Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "FRX."

Shares of FRX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

One share of FRX stock can currently be purchased for approximately C$8.61.

Fennec Pharmaceuticals has a market capitalization of C$223.89 million and generates C$170,000.00 in revenue each year.

Fennec Pharmaceuticals employs 9 workers across the globe.

The official website for Fennec Pharmaceuticals is fennecpharma.com.

Fennec Pharmaceuticals is headquartered at 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States.

Fennec Pharmaceuticals' mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company can be reached via phone at +1-919-6364530.